AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35999653 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% atropine eye drops
Number of subjects: 220
Study 35999653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 34418399 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-immunogenic staphylokinase (10 mg)
Number of subjects: 336
Study 34418399 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (0.9 mg/kg, maximum 90 mg)
Number of subjects: 336
Study 32707294 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test for Children (n = 103)
Number of subjects: 143
Study 32707294 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 40)
Number of subjects: 143
Study 34882313 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Manipulation Pulmonary Rehabilitation (PMPR) combined with Conventional Pulmonary Rehabilitation (CVPR)
Number of subjects: 86
Study 34882313 — intervention group
Group type: COMPARATOR
Intervention: Conventional Pulmonary Rehabilitation (CVPR) only
Number of subjects: 86
Study 33197681 — intervention group
Group type: EXPERIMENTAL
Intervention: Situational simulation training
Number of subjects: 92
Study 33197681 — intervention group
Group type: COMPARATOR
Intervention: Online teaching
Number of subjects: 92
Study 32854613 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia
Number of subjects: 40
Study 32854613 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 40
Study 33141078 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercises (16 weeks, twice per week, 45 min/session)
Number of subjects: 120
Study 34999324 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation for one year
Number of subjects: 600
Study 34999324 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 600
Study 33952398 — intervention group
Group type: EXPERIMENTAL
Intervention: SDS group (subcutaneous sufentanil and dexmedetomidine)
Number of subjects: 97
Study 33952398 — intervention group
Group type: EXPERIMENTAL
Intervention: SDI group (intravenous sufentanil and dexmedetomidine)
Number of subjects: 97
Study 33952398 — intervention group
Group type: COMPARATOR
Intervention: SS group (subcutaneous sufentanil)
Number of subjects: 97
Study 33952398 — intervention group
Group type: COMPARATOR
Intervention: SI group (intravenous sufentanil)
Number of subjects: 97
Study 35534903 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 94
Study 35534903 — intervention group
Group type: COMPARATOR
Intervention: Low-flow nasal cannula (LFNC)
Number of subjects: 94
Study 32960521 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa trigger
Number of subjects: 210
Study 32960521 — intervention group
Group type: COMPARATOR
Intervention: hCG trigger
Number of subjects: 210
Study 35799113 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially Inappropriate Medications (PIMs)
Number of subjects: 461
Study 35799113 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential Prescribing Omissions (PPOs)
Number of subjects: 461
Study 35799113 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimorbidity
Number of subjects: 461
Study 35799113 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of medications
Number of subjects: 461
Study 35799113 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of at least one PIM
Number of subjects: 461
Study 35799113 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of at least one PPO
Number of subjects: 461
Study 33452350 — intervention group
Group type: EXPERIMENTAL
Intervention: Volatile anesthesia (sevoflurane/remifentanil)
Number of subjects: 136
Study 33452350 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia (TIVA) (propofol/remifentanil)
Number of subjects: 136
Study 33452350 — intervention group
Group type: COMPARATOR
Intervention: TIVA
Number of subjects: 136
Study 33452350 — intervention group
Group type: EXPERIMENTAL
Intervention: Volatile anesthesia
Number of subjects: 136
Study 33452350 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TIVA and Volatile anesthesia
Number of subjects: 136
Study 34910219 — intervention group
Group type: EXPERIMENTAL
Intervention: Second 1-g TXA
Number of subjects: 220
Study 34910219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 32239164 — intervention group
Group type: EXPERIMENTAL
Intervention: MMV390048 80 mg
Number of subjects: 39
Study 32239164 — intervention group
Group type: EXPERIMENTAL
Intervention: MMV390048 40 mg
Number of subjects: 39
Study 32239164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 32239164 — intervention group
Group type: EXPERIMENTAL
Intervention: MMV390048 120 mg (predicted)
Number of subjects: 39
Study 36470231 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS (transcranial alternating current stimulation) targeting the left fronto-parietal network for 20 minutes
Number of subjects: 20
Study 36470231 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (transcranial direct current stimulation) targeting the left dorsolateral prefrontal cortex for 20 minutes
Number of subjects: 20
Study 36470231 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation for 20 minutes
Number of subjects: 20
Study 33201300 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) for solitary plasmacytoma
Number of subjects: 42
Study 32520718 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based tailored intervention
Number of subjects: 3995
Study 36059420 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of apatinib
Number of subjects: 116
Study 36059420 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine and oxaliplatin
Number of subjects: 116
Study 32542334 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel botanical formula (6 mg, 10 mg, or 14 mg of lutein)
Number of subjects: 360
Study 32542334 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lutein formula
Number of subjects: 360
Study 32542334 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 mg lutein formula
Number of subjects: 360
Study 32542334 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel botanical formula (all doses)
Number of subjects: 360
Study 32542334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 32542334 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Number of subjects: 360
Study 34843674 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based delivery (HBD)
Number of subjects: 2489
Study 34843674 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence clubs (AC)
Number of subjects: 2489
Study 34843674 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 2489
Study 32129791 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace wellness program and guidelines-oriented hypertension management protocol with community health center intervention; duration: 24 months.
Number of subjects: 4166
Study 32129791 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group); duration: 24 months.
Number of subjects: 4166
Study 36217243 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic congruence couple therapy (CCT)
Number of subjects: 46
Study 36217243 — intervention group
Group type: COMPARATOR
Intervention: Individual-based treatment-as-usual (TAU)
Number of subjects: 46
Study 33847856 — intervention group
Group type: EXPERIMENTAL
Intervention: 188Re-HEDP at 40 MBq/kg
Number of subjects: 54
Study 33847856 — intervention group
Group type: EXPERIMENTAL
Intervention: 188Re-HEDP at 50 MBq/kg
Number of subjects: 54
Study 34463814 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately hypofractionated radiotherapy (RT)
Number of subjects: 14
Study 34463814 — intervention group
Group type: COMPARATOR
Intervention: Normofractionated radiotherapy (RT)
Number of subjects: 14
Study 34780099 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMS‐G
Number of subjects: 30
Study 34780099 — intervention group
Group type: COMPARATOR
Intervention: CAU
Number of subjects: 30
Study 36252151 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula C (cannabidiol-rich preparation)
Number of subjects: 24
Study 36252151 — intervention group
Group type: COMPARATOR
Intervention: Placebo (blinded)
Number of subjects: 24
Study 36252151 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label active product (after crossover)
Number of subjects: 24
Study 34880011 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week semisupervised resistance training programme
Number of subjects: 60
Study 34880011 — intervention group
Group type: COMPARATOR
Intervention: Usual care (regular physical activity)
Number of subjects: 60
Study 35428274 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Kinetic Chain (OKC) exercises
Number of subjects: 66
Study 35428274 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed Kinetic Chain (CKC) exercises
Number of subjects: 66
Study 35428274 — intervention group
Group type: COMPARATOR
Intervention: Control group (education about clinical manifestations, risk factors, diagnosis, treatment, and nursing care for knee via printed materials)
Number of subjects: 66
Study 32359094 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex-stratified nomogram incorporating body compositions and clinical factors
Number of subjects: 414
Study 32359094 — intervention group
Group type: EXPERIMENTAL
Intervention: Low skeletal muscle index (myopenia), high intramuscular adipose tissue content (myosteatosis), and high visceral to subcutaneous adipose tissue area (adiposity)
Number of subjects: 414
Study 32359094 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 414
Study 34558966 — intervention group
Group type: EXPERIMENTAL
Intervention: ExerCube (EX)
Number of subjects: 28
Study 34558966 — intervention group
Group type: COMPARATOR
Intervention: Moderate endurance run (ER)
Number of subjects: 28
Study 32284380 — intervention group
Group type: EXPERIMENTAL
Intervention: Durlobactam (DUR) 1 g
Number of subjects: 124
Study 32284380 — intervention group
Group type: EXPERIMENTAL
Intervention: Durlobactam (DUR) 0.25 to 8 g (single ascending doses)
Number of subjects: 124
Study 32284380 — intervention group
Group type: EXPERIMENTAL
Intervention: Durlobactam (DUR) 0.25 to 2 g (multiple ascending doses every 6 hours for 29 doses)
Number of subjects: 124
Study 32284380 — intervention group
Group type: EXPERIMENTAL
Intervention: Durlobactam (DUR) 1 g with SUL (1 g) and/or IMI-CIL (0.5/0.5 g)
Number of subjects: 124
Study 35066737 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol-SR once a day
Number of subjects: 272
Study 35066737 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol-IR twice a day
Number of subjects: 272
Study 33637122 — intervention group
Group type: EXPERIMENTAL
Intervention: StayBalanced balance training programme with close facilitation (support and close follow-ups)
Number of subjects: 0
Study 33637122 — intervention group
Group type: COMPARATOR
Intervention: StayBalanced balance training programme with access to the website only
Number of subjects: 0
Study 32503608 — intervention group
Group type: EXPERIMENTAL
Intervention: YinQiSanHuang-antiviral decoction with entecavir
Number of subjects: 802
Study 32503608 — intervention group
Group type: COMPARATOR
Intervention: Placebo with entecavir
Number of subjects: 802
Study 35748900 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-CAD positive scores (≥ 10%)
Number of subjects: 500
Study 35748900 — intervention group
Group type: COMPARATOR
Intervention: AI-CAD
Number of subjects: 500
Study 35748900 — intervention group
Group type: COMPARATOR
Intervention: Experienced breast radiologist
Number of subjects: 500
Study 32441353 — intervention group
Group type: COMPARATOR
Intervention: Trauma patients
Number of subjects: 37
Study 35248012 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise
Number of subjects: 100
Study 35248012 — intervention group
Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 100
Study 34295663 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (37.5 mg/m2, D1, D8) combined with Carboplatin (AUC 5.0) (DC group)
Number of subjects: 52
Study 34295663 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,000 mg/m2, D1, D8) combined with Carboplatin (AUC 5.0) (GC group)
Number of subjects: 52
Study 34295663 — intervention group
Group type: COMPARATOR
Intervention: Previous literature anti-tumor therapy only group
Number of subjects: 52
Study 32325794 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacilli (L.) rhamnosus GR‐1 and L. reuteri RC‐14, 5 × 10^9 CFU, 2 capsules/day for 2 months
Number of subjects: 40
Study 32325794 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 40
Study 32325794 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment (both groups)
Number of subjects: 40
Study 32325794 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment
Number of subjects: 40
Study 36116393 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilapan-S
Number of subjects: 0
Study 36116393 — intervention group
Group type: COMPARATOR
Intervention: Propess
Number of subjects: 0
Study 33533901 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid withdrawal
Number of subjects: 386
Study 33533901 — intervention group
Group type: COMPARATOR
Intervention: Continued corticosteroids
Number of subjects: 386
Study 33376176 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct oral betamethasone for 2 days
Number of subjects: 700
Study 33376176 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 700
Study 32573808 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-angle endoscope (VAE)
Number of subjects: 5
Study 32573808 — intervention group
Group type: COMPARATOR
Intervention: Fixed-angle endoscope (FAE)
Number of subjects: 5
Study 32573808 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ventilation
Number of subjects: 5
Study 32573808 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscope type
Number of subjects: 5
Study 33219115 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive tendon-loading exercises (PTLE)
Number of subjects: 76
Study 33219115 — intervention group
Group type: COMPARATOR
Intervention: Eccentric exercise therapy (EET)
Number of subjects: 76
Study 32019557 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid restriction + low CVP (Group L)
Number of subjects: 140
Study 32019557 — intervention group
Group type: COMPARATOR
Intervention: Fluid restriction (Group F)
Number of subjects: 140
Study 34092381 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP) program for eight weeks
Number of subjects: 20
Study 34092381 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 20
Study 34407775 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Pregnancy Service
Number of subjects: 49
Study 33568491 — intervention group
Group type: EXPERIMENTAL
Intervention: Girl2Girl
Number of subjects: 948
Study 33568491 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 948
Study 36087588 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 μg MenB-FHbp
Number of subjects: 796
Study 36087588 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 μg MenB-FHbp
Number of subjects: 796
Study 36087588 — intervention group
Group type: COMPARATOR
Intervention: Control (HAV vaccine and saline)
Number of subjects: 796
Study 34009435 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning exercise
Number of subjects: 25
Study 34009435 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening exercise
Number of subjects: 25
Study 34009435 — intervention group
Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 25
Study 33884691 — intervention group
Group type: COMPARATOR
Intervention: HOB elevation to <30°
Number of subjects: 60
Study 33884691 — intervention group
Group type: EXPERIMENTAL
Intervention: HOB elevation to 30°
Number of subjects: 60
Study 33884691 — intervention group
Group type: EXPERIMENTAL
Intervention: HOB elevation to 45°
Number of subjects: 60
Study 33939054 — intervention group
Group type: EXPERIMENTAL
Intervention: Group well child care
Number of subjects: 175
Study 33939054 — intervention group
Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 175
Study 32220375 — intervention group
Group type: EXPERIMENTAL
Intervention: Early post-operative feeding (consumption of solid food on POD1)
Number of subjects: 301
Study 32220375 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tolerance of solid food (consumption of at least half of three meals on POD1 or 2 without vomiting)
Number of subjects: 301
Study 32220375 — intervention group
Group type: COMPARATOR
Intervention: Provision of pre-operative bowel preparation
Number of subjects: 301
Study 32220375 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic/laparoscopic assisted surgery
Number of subjects: 301
Study 36184994 — intervention group
Group type: EXPERIMENTAL
Intervention: Linked color imaging (LCI)
Number of subjects: 120
Study 36184994 — intervention group
Group type: COMPARATOR
Intervention: White light imaging (WLI)
Number of subjects: 120
Study 32901830 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro F IOL
Number of subjects: 45
Study 32901830 — intervention group
Group type: EXPERIMENTAL
Intervention: POD F IOL
Number of subjects: 45
Study 32901830 — intervention group
Group type: EXPERIMENTAL
Intervention: POD FT IOL
Number of subjects: 45
Study 32901830 — intervention group
Group type: COMPARATOR
Intervention: All IOL models
Number of subjects: 45
Study 35792365 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg
Number of subjects: 100
Study 35792365 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.80 mg
Number of subjects: 100
Study 35792365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 33515782 — intervention group
Group type: EXPERIMENTAL
Intervention: NOURISH-T+ intervention
Number of subjects: 260
Study 33515782 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 260
Study 36287567 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone (10 or 20 mg once daily)
Number of subjects: 13026
Study 36287567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13026
Study 32003275 — intervention group
Group type: EXPERIMENTAL
Intervention: Project ADHerence Education and Risk Evaluation (ADHERE)
Number of subjects: 30
Study 32003275 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Adherence and Care Engagement (MACE)
Number of subjects: 30
Study 32003275 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study 35123419 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ischemic conditioning (ISCON) prior to esophagectomy
Number of subjects: 20
Study 35123419 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ischemic conditioning (ISCON)
Number of subjects: 20
Study 33813569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 0.5 mg/kg
Number of subjects: 80
Study 33813569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 1 mg/kg
Number of subjects: 80
Study 33813569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Number of subjects: 80
Study 33813569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 35252455 — intervention group
Group type: EXPERIMENTAL
Intervention: Acutreatment (n = 30)
Number of subjects: 57
Study 35252455 — intervention group
Group type: COMPARATOR
Intervention: Sham Acutreatment (placebo, n = 27)
Number of subjects: 57
Study 32555144 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based self-assessments for depression severity
Number of subjects: 84
Study 32555144 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based self-assessments for mania severity
Number of subjects: 84
Study 35115269 — intervention group
Group type: EXPERIMENTAL
Intervention: Female trainee (n = 50)
Number of subjects: 107
Study 35115269 — intervention group
Group type: COMPARATOR
Intervention: Male trainee (n = 57)
Number of subjects: 107
Study 35750637 — intervention group
Group type: EXPERIMENTAL
Intervention: AdVEGF‐D gene therapy
Number of subjects: 30
Study 35750637 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 32681063 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (recorded maternal singing/heartbeat)
Number of subjects: 100
Study 32681063 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 100
Study 34928719 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Concerns Inventory intervention
Number of subjects: 368
Study 34928719 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 368
Study 34405233 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset stage III colon adenocarcinoma (EO-CC)
Number of subjects: 35713
Study 32796009 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay in diabetes onset by 1 year
Number of subjects: 3058
Study 32796009 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay in diabetes onset by 9 years
Number of subjects: 3058
Study 36129700 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural Metascore (SMS) using HRT rim area, Cirrus OCT average RNFL thickness, and Spectralis OCT RNFL global thickness normalized on a scale of 0 to 100.
Number of subjects: 1824
Study 36129700 — intervention group
Group type: EXPERIMENTAL
Intervention: Average grades assigned by clinicians based on structural measurement printouts alone.
Number of subjects: 1824
Study 36129700 — intervention group
Group type: EXPERIMENTAL
Intervention: Average grades assigned by clinicians based on metascore plots alone.
Number of subjects: 1824
Study 36129700 — intervention group
Group type: EXPERIMENTAL
Intervention: Average grades assigned by clinicians based on printouts + metascore plots.
Number of subjects: 1824
Study 36129700 — intervention group
Group type: EXPERIMENTAL
Intervention: Average absolute predictive ability of the SMS.
Number of subjects: 1824
Study 34587803 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic arm‐assisted bi‐unicompartmental knee arthroplasty (bi‐UKA)
Number of subjects: 76
Study 34587803 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanically aligned total knee arthroplasty (TKA)
Number of subjects: 76
Study 32804308 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in allocentric spatial updating
Number of subjects: 40
Study 32804308 — intervention group
Group type: COMPARATOR
Intervention: Feedback only
Number of subjects: 40